Recent clinical guidelines have emphasized the importance of screening for cognitive
impairment in older adults with diabetes, however, there is still a lack of understanding about …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment …

Dementia is a permanent illness characterized by mental instability, memory loss, and
cognitive decline. Many studies have demonstrated an association between diabetes and …

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis
of brain impairment caused by chronic hyperglycemia is complex and includes …

The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the
last few decades. Since insulin and insulin receptors are known to be present in the brain …

Metabolic and neurodegenerative disorders have a growing prevalence in Western
countries. Available epidemiologic and neurobiological evidences support the existence of a …

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both
have the same pathogenesis (eg, insulin resistance), drugs used to treat T2DM have been …

The current understanding of neurodegenerative processes in sporadic diseases such as
Alzheimer's disease (AD), Parkinson's disease (PD) or multiple sclerosis is very limited …

The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's
disease (PD) reflects an incomplete knowledge of the underlying disease processes …